Abstract:Correction to: Eur Rev Med Pharmacol Sci 2023; 27 (9): 4098-4102. DOI: 10.26355/eurrev_202305_32317-PMID: 37203835-published online on May 15, 2023. After publication, the authors applied a correction in the Funding section. The section has been amended as follows: This study was supported by the research program of Jilin Provincial Science and Technology Department (No. 20190201011J). There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/32317.

Corrigendum to "trend of HIV-1 Drug Resistance in China: A Systematic Review and Meta-Analysis of Data Accumulated over 17 Years (2001-2017)" [eclinicalmedicine 18 (2020) 100238].

Erratum to “The Feasibility of Xpert MTB/RIF Testing to Detect Rifampicin Resistance among Childhood Tuberculosis for Prevalence Surveys in Northern China”

Corrigendum to “sex Differences in HIV Treatment Outcomes and Adherence by Exposure Groups among Adults in Guangdong, China: A Retrospective Observational Cohort Study” [eclinicalmedicine 22 (2020) 100351]

Correction: Aliskiren Therapy in Hypertension and Cardiovascular Disease: a Systematic Review and a Meta-Analysis

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Corrigendum: Digitizing tuberculosis treatment monitoring in Wuhan city, China, 2020–2021: Impact on medication adherence

Corrigendum: A Comparison of COVID-19 Stigma and AIDS Stigma During the COVID-19 Pandemic: A Cross-Sectional Study in China

Corrigendum: Delayed Diagnosis and Treatment of Cancer Patients During the COVID-19 Pandemic in Henan, China: an Interrupted Time Series Analysis

A Retrospective Study On The Use Of Chinese Patent Medicine In 24 Medical Institutions For Covid-19 In China (Vol 11, 574562, 2020)

Corrigendum: Potential Mechanisms of Action of Chinese Patent Medicines for COVID-19: A Review

Corrigendum to “effects of a Symptom Management Intervention Based on Group Sessions Combined with a Mobile Health Application for Persons Living with HIV in China: A Randomized Controlled Trial” [int J Nurs Sci 8 (2021) 370–379]

Author Correction: BHMT Polymorphism and Susceptibility to PTE in Chinese Patients.

Corrigendum: Impact of Serum Uric Acid Lowering and Contemporary Uric Acid-Lowering Therapies on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.

Erratum: Analysis on the medication rule of traditional Chinese medicine in the treatment of COVID-19 patients: Erratum

Corrigendum: Comparative Analysis of Lower Genital Tract Microbiome Between PCOS and Healthy Women.

Corrigendum: Molecular epidemiology and mechanism of Klebsiella pneumoniae resistance to ertapenem but not to other carbapenems in China

Corrigendum: Distinct patterns of fasting plasma glucose and lipid profile levels over time in adults tested positive for HIV on HAART in Shanghai, China, revealed using growth mixture models.

Corrigendum: A matter of life or death: Productively infected and bystander CD4 T Cells in early HIV infection

Erratum: Epidemiology of Genital Chlamydial Infection in China in 2019: Erratum

Corrigendum: Multicenter Analysis of Liver Injury Patterns and Mortality in COVID-19

Corrigendum to Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review